A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (NCT05207670)

🧪 Interventions in This Study

• Mosunetuzumab (Cohorts A-C) (DRUG)
• Mosunetuzumab (Cohorts D-E) (DRUG)
• Tocilizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (39 Sites)

Showing the first 25 of 39 sites.

• Infirmary Cancer Care — Mobile, Alabama
• Alaska Oncology & Hematology, LLC — Anchorage, Alaska
• Mayo Clinic Arizona — Phoenix, Arizona
• City of Hope — Duarte, California
• Rocky Mountain Cancer Centers (Aurora) - USOR — Aurora, Colorado
• Medical Oncology Hematology Consultants — Newark, Delaware
• SCRI Florida Cancer Specialists South — Fort Myers, Florida
• Mayo Clinic Jacksonville - PPDS — Jacksonville, Florida
• Cancer Specialists of North Florida - Jacksonville — Jacksonville, Florida
• Florida Cancer Specialists - NORTH - SCRI - PPDS — St. Petersburg, Florida
• Florida Cancer Specialists - EAST - SCRI - PPDS — West Palm Beach, Florida
• Mission Blood and Cancer - MercyOne Cancer Center — Des Moines, Iowa
• University of Kansas Medical Center — Westwood, Kansas
• Oncology Hematology Care - SCRI — Zachary, Louisiana
• American Oncology Partners of Maryland, PA — Bethesda, Maryland
• Mayo Clinic - PPDS — Rochester, Minnesota
• St. Vincent Frontier Cancer Center — Billings, Montana
• Astera Cancer Care East Brunswick — East Brunswick, New Jersey
• San Juan Oncology Associates — Farmington, New Mexico
• New York Oncology Hematology, P.C. — Albany, New York
• New York Cancer & Blood Specialists - New Hyde Park — New Hyde Park, New York
• NY Cancer & Blood Specialist — New York, New York
• North Shore Hematology Oncology Association PC — Shirley, New York
• New York Cancer & Blood Specialists - Bronx — The Bronx, New York
• Oncology Hematology Care Inc - Cincinnati - USOR — Cincinnati, Ohio

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-Hodgkin Lymphoma

• A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma — Duarte, California
• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma — Tucson, Arizona
• AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma — St Louis, Missouri
• Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma — Chicago, Illinois
• Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy — St Louis, Missouri

Explore by condition: All Non-Hodgkin Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.